{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:25:15Z","timestamp":1789543515494,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,3,28]],"date-time":"2007-03-28T00:00:00Z","timestamp":1175040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Objectives:\u2002<\/jats:italic>In individuals without iron deficiency, the soluble transferrin receptor (sTfR) directly reflects the erythropoietic activity. This study investigated sTfR concentrations in ineffective, dysplastic erythropoiesis in myelodysplastic syndrome (MDS). <jats:italic>Methods:\u2002<\/jats:italic>To exclude influences of other myeloid cells on sTfR, only patients with refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS) and 5q<jats:sup>\u2013<\/jats:sup> syndrome were included. sTfR was measured nephelometrically (normal range 0.81\u20131.75\u2003mg\/L). <jats:italic>Results:\u2002<\/jats:italic>Thirty\u2010four untreated MDS patients (RA\u2003=\u200314, RARS\u2003=\u200310, 5q<jats:sup>\u2013<\/jats:sup> syndrome\u2003=\u200310) were enrolled and analysed. The mean sTfR value of all MDS patients (1.30\u2003\u00b1\u20030.8\u2003mg\/L, range 0.2\u20133.8) did not differ from our control group. In 5q<jats:sup>\u2013<\/jats:sup> syndrome, the mean sTfR concentration (0.80\u2003\u00b1\u20030.5\u2003mg\/L) was significantly lower than in RA (1.32\u2003\u00b1\u20030.4\u2003mg\/L, <jats:italic>P<\/jats:italic>\u2003=\u20030.02) and RARS (1.75\u2003\u00b1\u20031.1\u2003mg\/L, <jats:italic>P<\/jats:italic>\u2003=\u20030.03). Subdividing MDS according to their amount of erythroid mass in bone marrow a significant difference of sTfR between patients with decreased (0.70\u2003\u00b1\u20030.4\u2003mg\/L), normal (1.32\u2003\u00b1\u20030.4\u2003mg\/L) and increased (2.06\u2003\u00b1\u20030.9\u2003mg\/L) erythropoiesis was observed. MDS patients with sTfR values below the reference range of 0.81\u2003mg\/L required transfusions in 90% of cases and showed higher erythropoietin levels compared to MDS patients with sTfR levels \u22650.81\u2003mg\/L (<jats:italic>P<\/jats:italic>\u2003=\u20030.01). There was a good agreement between sTfR and the amount of polychromatic erythroblasts observed (<jats:italic>r<\/jats:italic>\u2003=\u20030.68, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). <jats:italic>Conclusion:\u2002<\/jats:italic>In conclusion, the serum concentration of sTfR reflects erythropoietic activity in MDS, but it is in particular determined by the degree of erythroid maturation and the severity of ineffective erythropoiesis. Low sTfR values in MDS are associated with a reduced, poorly differentiated erythropoiesis and requirement of blood transfusions.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2007.00863.x","type":"journal-article","created":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T16:59:50Z","timestamp":1180371590000},"page":"8-16","source":"Crossref","is-referenced-by-count":8,"title":["The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome"],"prefix":"10.1111","volume":"79","author":[{"given":"Georgia","family":"Metzgeroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul La","family":"Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dorn\u2010Beineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hastka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(82)90547-8"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb04120.x"},{"key":"e_1_2_6_4_2","first-page":"1","article-title":"The soluble transferrin receptor: biological aspects and clinical usefulness as quantitative measure of erythropoiesis","volume":"77","author":"Beguin Y","year":"1992","journal-title":"Haematologica"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(03)00005-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.6.1955.1955"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2000.054"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.1.102.102"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ajcn\/46.5.840","article-title":"Screening test for iron overload","volume":"46","author":"Skikne BS","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1163\/15685590260461048"},{"key":"e_1_2_6_11_2","first-page":"151","article-title":"Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters","volume":"8","author":"Bowen DT","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.me.44.020193.000431"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000040707"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203669"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365519309090703"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076521"},{"key":"e_1_2_6_17_2","first-page":"493","article-title":"Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes","volume":"79","author":"Musto P","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_6_18_2","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-94944-9"},{"key":"e_1_2_6_20_2","volume-title":"Das menschliche Knochenmark","author":"Rohr K","year":"1960"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00515.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1209.1209"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01085.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08909.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01313.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050166"},{"key":"e_1_2_6_27_2","first-page":"265","article-title":"Low serum levels of tumor necrosis factor and interleukin\u20101 beta in myelodysplastic syndromes responsive to recombinant erythropoietin","volume":"79","author":"Musto P","year":"1994","journal-title":"Haematologica"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2340.2340"},{"key":"e_1_2_6_29_2","first-page":"27","article-title":"Prediction of response to optimize outcome of treatment with erythropoietin","volume":"25","author":"Beguin Y","year":"1998","journal-title":"Semin Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2007.00863.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2007.00863.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:19:42Z","timestamp":1697372382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2007.00863.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1600-0609.2007.00863.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00863.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,28]]}}}